Peer Review History
| Original SubmissionJanuary 14, 2026 |
|---|
|
Dear Dr. Liang Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Jun 21 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Diana Laila Ramatillah, PhD Academic Editor PLOS One Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 2. Thank you for stating the following financial disclosure: “Science and Technology Project for the Development and Enhancement of Nursing Discipline at The First People's Hospital of Changzhou, yy2023001 and yy2023015.” Please state what role the funders took in the study. If the funders had no role, please state: "The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript." If this statement is not correct you must amend it as needed. Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf. 3. We note that your Data Availability Statement is currently as follows: [All relevant data are within the manuscript and its Supporting Information files. ] Please confirm at this time whether or not your submission contains all raw data required to replicate the results of your study. Authors must share the “minimal data set” for their submission. PLOS defines the minimal data set to consist of the data required to replicate all study findings reported in the article, as well as related metadata and methods (https://journals.plos.org/plosone/s/data-availability#loc-minimal-data-set-definition). For example, authors should submit the following data: - The values behind the means, standard deviations and other measures reported; - The values used to build graphs; - The points extracted from images for analysis. Authors do not need to submit their entire data set if only a portion of the data was used in the reported study. If your submission does not contain these data, please either upload them as Supporting Information files or deposit them to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. For a list of recommended repositories, please see https://journals.plos.org/plosone/s/recommended-repositories. If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially sensitive information, data are owned by a third-party organization, etc.) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent. If data are owned by a third party, please indicate how others may request data access. 4. Please be informed that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. Please remove any funding-related text from the manuscript. 5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 6. If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Additional Editor Comments (if provided): 1. Please mention in the method how many participants in this research 2. Please make analysis between sociodemographic and the scoring 3. Explain in the discussion about correlation sociodemographic and the scoring [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #1: No Reviewer #2: Yes Reviewer #3: No Reviewer #4: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #1: Yes Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: No ********** Reviewer #1: The manuscript demonstrates high technical rigor, appropriate statistical analysis, and strong psychometric evidence. Addressing the data availability issue and clarifying study dates will make it fully compliant with PLOS ONE criteria. Regarding more details, I have added an attachment file including what i must be check and the reasoning for all responses above. Reviewer #2: I have carefully reviewed the manuscript and find it to be clear and well‑structured The arguments are coherent, the methodology is appropriate, and the conclusions are consistent with the presented analysis. Reviewer #3: I am not sure if the authors have provided all the data that partain to this study because a link was not provided to be able to assess the data. They only said that it can be provided on reasonable request. The manuscript discussed topical issue relating to the care of patients with chronic kidney disease. Correcting the issues mentioned in the review comment will enrich the rigosity of the manuscript. Reviewer #4: It is a great work with great public health significance. It is a work with relevant clinical problem, clear innovation, large validation sample, multiple development steps, and strong reliability statistics with acceptable factor analysis. However, below are major points that should be considered 1. The manuscript needs serious professional editing. Examples: “may be crucial” looks too weak; “was also accepted” feels awkward; “we conceptualize” has tense issue; “assessment work better guarantees” has incorrect grammar. Additionally, there are many spacing/punctuation issues = I recommend the authors to use native English editing. 2. In submission form it says all relevant data are within manuscript and supporting files. But in manuscript it says “Data available from corresponding author on reasonable request”. These contradict each other. = The authors should fix this. 3. There are some issues with timeline consistency. The Methods says “Study conducted August 2024 to December 2024”. But recruitment says 01/12/2022 to 01/10/2024. = Need correction or explanation. 4. The criterion validity needs better Justification. You used Barthel Index with correlation = -0.715. It is reasonable, but Barthel measures ADL, not dialysis dependency. Why you used Barthel instead of nursing workload or dependency gold standard? = This needs stronger explanation. 5. Some Statistical Descriptions Are Weak. Examples: “ICC was accepted”, and “good discriminative ability”. = It needs confidence intervals for alpha if possible. And also need clearer rationale for retaining Item 3.3 despite low correlation. And below are minor comments 6. Ethical Statement Needs Minor Editing. Use: Written informed consent was obtained from all participants. Not “consents”. 7. All patients are from one hospital in Changzhou. This limits generalizability. So, it needs stronger limitation statement. 8. Who exactly completed HD-CDS? Sometimes says nurses scored it. Sometimes patients participated. This needs clarity. Is it observer-rated? Nurse-administered? Patient interview? 9. The current title too long. Better: Development and Psychometric Validation of the Hemodialysis Patient Care Dependency Scale (HD-CDS) ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #1: Yes: Abdelrahim Dafalla Elhag Ahmed Reviewer #2: No Reviewer #3: No Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications.
|
| Revision 1 |
|
Dear Dr. liang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Sep 17 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Wisit Kaewput, MD, FRCP, FRCPSG, FASN, FAcadMEd Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Thank you for the detailed point-by-point responses and the substantial revisions made to the manuscript. The manuscript is considerably clearer, and most of my previous concerns have been satisfactorily addressed. Before the manuscript can be considered further, I recommend the following minor corrections. 1. Please verify and report the test–retest sample size consistently throughout the manuscript, abstract, response letter, tables, and Supporting Information. Different sections appear to report either 39 or 40 participants. If 40 participants were invited but only 39 were included in the analysis, please state this explicitly and briefly explain the exclusion or missing assessment. 2. The ethics statement in the submission information still states, “Written informed consents were obtained from all participants.” Please revise this to, “Written informed consent was obtained from all participants.” Please also ensure that the ethics statement entered in the submission system is identical to the statement in the Methods section. 3. Because the Barthel Index is not a gold-standard measure of hemodialysis-specific care dependency, the observed correlation may be more accurately described as evidence of convergent validity rather than definitive criterion validity. Please either replace “criterion validity” with “convergent validity” throughout the Abstract, Methods, Results, Discussion, tables, and Supporting Information, or consistently describe the Barthel Index as a proxy criterion and clearly acknowledge the limitations of this terminology. 4. Some statements remain stronger than the available evidence supports, including descriptions of the HD-CDS as a “reliable and effective” or fully “validated” instrument and suggestions that it can already guide targeted nursing interventions or staffing allocation. The present study provides promising initial evidence of content validity, internal consistency, test–retest reliability, and exploratory structural validity, but it does not directly evaluate staffing decisions, nursing workload, safety outcomes, or clinical effectiveness. Please consider revising the conclusion as follows: “The HD-CDS demonstrated promising preliminary psychometric properties in a single-center sample and may provide a useful framework for assessing care dependency among patients undergoing hemodialysis. Further multicenter studies, including independent structural validation and inter-rater reliability assessment, are required before routine clinical implementation.” Similarly, please remove or qualify claims that the instrument has “superior” assessment capabilities or can reduce falls, infections, or other safety events unless these outcomes were directly evaluated. 5. Please identify the specific factor-extraction method used rather than reporting only the rotation method. In addition, the manuscript states that the loading threshold of 0.40 was calculated using 5.152/√(n−2). For n = 395, this calculation gives approximately 0.26 rather than 0.40. Please correct this statement. If 0.40 was selected as an a priori practical threshold, please state this directly and remove the inconsistent calculation. 6. The social-support domain had a Cronbach’s α of 0.737 and a split-half coefficient of 0.755, whereas the Methods specify values greater than 0.80 as acceptable. Please reconcile this inconsistency. The social-support domain may be described as showing moderate or acceptable preliminary internal consistency, but the manuscript should not state that every dimension exceeded the prespecified threshold. The overall scale reliability remains satisfactory. 7. Please conduct a final review of the manuscript to ensure that very small p values are reported as “p < 0.001” rather than “p = 0.000,” the domain names are used consistently throughout, duplicated or tracked-change text is removed, the clean manuscript contains no editorial comments, and the distinction between initial psychometric evaluation and external clinical validation is maintained consistently. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed Reviewer #4: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? -->?> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available??> The PLOS Data policy Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English??> Reviewer #2: Yes Reviewer #3: Yes Reviewer #4: Yes ********** Reviewer #2: The authors have addressed the earlier concerns; however, the limitation section would benefit from further elaboration, particularly regarding the justification of generalizability. The current formulation acknowledges this issue only “to some extent,” which leaves the reader without a clear understanding of how the findings can be applied beyond the study context. Strengthening this part with a more explicit and well‑reasoned justification—one that clearly aligns with and supports your final argument—is necessary before the manuscript is ready for publication. Reviewer #3: Thank you for addressing the reviewers' comments and for the substantial revisions made to the manuscript. The revised version is considerably improved in terms of clarity, methodological reporting, and conceptual framework. You have adequately addressed my major concerns by: Strengthening the conceptualization of care dependency and clearly distinguishing it from frailty and functional status, while linking the concept to the three domains of the HD-CDS. Correcting the inconsistencies in the study timeline. Correcting the description of the item-level content validity index (I-CVI) calculation and clarifying that the analyses were performed using the standard approach. Revising the interpretation of Kendall's W values to avoid overstating expert consensus. I also note that the data availability statement has been revised, and the authors have indicated that the anonymized datasets supporting the findings have been provided as supporting information, in keeping with the journal's requirements. Overall, I believe the manuscript has been substantially improved and is suitable for publication Reviewer #4: The authors have comprehensively addressed all reviewer feedback, and the manuscript has been significantly improved. I am pleased with the final version and strongly recommend acceptance for publication. ********** what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy Reviewer #2: No Reviewer #3: Yes: Abdulakeem Ahmed Reviewer #4: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 2 |
|
PLOS One Dear Dr. liang, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. ============================== ACADEMIC EDITOR: Thank you for submitting the revised version of your manuscript, “Development and preliminary psychometric evaluation of the hemodialysis patient care dependency scale (HD-CDS).” The manuscript has been substantially improved, and the authors have responded carefully to the previous editorial and reviewer comments. In particular, the revised manuscript provides clearer reporting of the test–retest sample, appropriately characterizes the association with the Barthel Index as convergent validity, clarifies the factor extraction and rotation procedures, moderates claims regarding validation and clinical application, and provides a more appropriately cautious discussion of generalizability. Only a small number of editorial and methodological consistency issues remain before the manuscript can be considered for acceptance. First, please ensure consistency in the reported threshold for the item-level content validity index (I-CVI). The Methods state that an I-CVI of ≥0.78 is considered acceptable, whereas the Results state that the observed I-CVI values of 0.833–1.000 exceeded a threshold of 0.74. Please reconcile this discrepancy and use the prespecified threshold consistently throughout the manuscript and Supporting Information. Second, please harmonize the interpretation of the intraclass correlation coefficient (ICC) across the Methods and Results. The Methods provide one set of interpretive thresholds for test–retest reliability, whereas the Results additionally state that an ICC >0.75 was considered acceptable and subsequently interpret values exceeding 0.70 as indicating good reliability. Please use a single prespecified interpretive framework consistently throughout the manuscript and avoid introducing a different threshold in the Results unless it was defined a priori and appropriately referenced. Please also conduct one final consistency check of the revised manuscript and Supporting Information to ensure that terminology, statistical thresholds, and interpretations are fully aligned and that the ethics statement entered in the submission system is identical to that reported in the manuscript. These are minor issues and do not require substantial additional analysis. A careful revision addressing the points above should place the manuscript in a strong position for final consideration. A point-by-point response indicating the changes made would be appreciated. ============================== Please submit your revised manuscript by Sep 25 2026 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.
If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. As the corresponding author, your ORCID iD is verified in the submission system and will appear in the published article. PLOS supports the use of ORCID, and we encourage all coauthors to register for an ORCID iD and use it as well. Please encourage your coauthors to verify their ORCID iD within the submission system before final acceptance, as unverified ORCID iDs will not appear in the published article. Only the individual author can complete the verification step; PLOS staff cannot verify ORCID iDs on behalf of authors. We look forward to receiving your revised manuscript. Kind regards, Wisit Kaewput, MD, FRCP, FRCPSG, FASN, FAcadMEd Academic Editor PLOS One Journal Requirements: If the reviewer comments include a recommendation to cite specific previously published works, please review and evaluate these publications to determine whether they are relevant and should be cited. There is no requirement to cite these works unless the editor has indicated otherwise. Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice. Additional Editor Comments: Thank you for submitting the revised version of your manuscript, “Development and preliminary psychometric evaluation of the hemodialysis patient care dependency scale (HD-CDS).” The manuscript has been substantially improved, and the authors have responded carefully to the previous editorial and reviewer comments. In particular, the revised manuscript provides clearer reporting of the test–retest sample, appropriately characterizes the association with the Barthel Index as convergent validity, clarifies the factor extraction and rotation procedures, moderates claims regarding validation and clinical application, and provides a more appropriately cautious discussion of generalizability. Only a small number of editorial and methodological consistency issues remain before the manuscript can be considered for acceptance. First, please ensure consistency in the reported threshold for the item-level content validity index (I-CVI). The Methods state that an I-CVI of ≥0.78 is considered acceptable, whereas the Results state that the observed I-CVI values of 0.833–1.000 exceeded a threshold of 0.74. Please reconcile this discrepancy and use the prespecified threshold consistently throughout the manuscript and Supporting Information. Second, please harmonize the interpretation of the intraclass correlation coefficient (ICC) across the Methods and Results. The Methods provide one set of interpretive thresholds for test–retest reliability, whereas the Results additionally state that an ICC >0.75 was considered acceptable and subsequently interpret values exceeding 0.70 as indicating good reliability. Please use a single prespecified interpretive framework consistently throughout the manuscript and avoid introducing a different threshold in the Results unless it was defined a priori and appropriately referenced. Please also conduct one final consistency check of the revised manuscript and Supporting Information to ensure that terminology, statistical thresholds, and interpretations are fully aligned and that the ethics statement entered in the submission system is identical to that reported in the manuscript. These are minor issues and do not require substantial additional analysis. A careful revision addressing the points above should place the manuscript in a strong position for final consideration. A point-by-point response indicating the changes made would be appreciated. [Note: HTML markup is below. Please do not edit.] [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] To ensure your figures meet our technical requirements, please review our figure guidelines: https://journals.plos.org/plosone/s/figures You may also use PLOS’s free figure tool, NAAS, to help you prepare publication quality figures: https://journals.plos.org/plosone/s/figures#loc-tools-for-figure-preparation. NAAS will assess whether your figures meet our technical requirements by comparing each figure against our figure specifications. |
| Revision 3 |
|
Development and preliminary psychometric evaluation of the hemodialysis patient care dependency scale (HD-CDS) PONE-D-25-67462R3 Dear Dr. liang, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. For questions related to billing, please contact billing support. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Wisit Kaewput, MD, FRCP, FRCPSG, FASN, FAcadMEd Academic Editor PLOS One Additional Editor Comments (optional): Accept as is. Reviewers' comments: |
| Formally Accepted |
|
PONE-D-25-67462R3 PLOS One Dear Dr. liang, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS One. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset You will receive further instructions from the production team, including instructions on how to review your proof when it is ready. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few days to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. You will receive an invoice from PLOS for your publication fee after your manuscript has reached the completed accept phase. If you receive an email requesting payment before acceptance or for any other service, this may be a phishing scheme. Learn how to identify phishing emails and protect your accounts at https://explore.plos.org/phishing. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS One and supporting open access. Kind regards, PLOS One Editorial Office Staff on behalf of Dr. Wisit Kaewput Academic Editor PLOS One |
Open letter on the publication of peer review reports
PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.
We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.
Learn more at ASAPbio .